Posted by Michael Wonder on 29 Nov 2016
Development challenges for medicines for central nervous system disorders
29 November 2016 - EMA conducts analysis of applications submitted between 1995 and 2014.
An analysis of over 100 applications submitted between 1995 and 2014 to the EMA shows that various challenges can arise in the development of medicines meant to treat central nervous system (CNS) disorders, and highlights the importance of an appropriate design of early-stage clinical trials for future success in the development.
This analysis of the applications for medicines in the fields of psychiatry or neurologyExternal link icon, led by staff members of EMA, is published today in Nature Reviews Drug Discovery.
